BAM15 Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about BAM15 dosing — protocols, safety, and where to buy.
Dose Range
Research compound — no established human doses. Animal studies use 10-100 mg/kg
Dosage Calculator
Calculate exact dosing for BAM15.
Dosing Protocols
There is no beginner protocol for BAM15, and this section exists specifically to explain why. The correct beginner protocol is: do not use BAM15. If you are new to metabolic pharmacology and looking for your first compound to try, BAM15 is the worst possible starting point because it is the least clinically validated option in a category that already requires caution. The appropriate first-line interventions for body composition and metabolic health are: a properly structured caloric deficit with adequate protein (1.6-2.2 g/kg/day), resistance training 3-5 times per week, 150-300 minutes of moderate-intensity cardiovascular exercise per week, 7-9 hours of sleep per night, and stress management sufficient to keep cortisol patterns normal. These interventions deliver 80% of the metabolic benefit BAM15 is proposed to produce, with zero pharmacologic risk, and they are the baseline that any legitimate clinician would recommend before considering any metabolic drug. The second-line interventions, if the first-line basics are fully optimized and body composition or metabolic health goals remain unmet, are FDA-approved medications with Phase 3 efficacy and safety data: GLP-1 receptor agonists (Semaglutide, Tirzepatide), metformin, SGLT2 inhibitors for people with type 2 diabetes, bupropion-naltrexone for appetite issues, and — in appropriate patients — bariatric surgery, which remains the most effective long-term intervention for severe obesity. These options require a prescriber and involve real risks, but the risks are characterized, the benefits are quantified, and the therapeutic window has been established through trials in tens of thousands of people. BAM15 offers none of this. If after reading the sections above you still intend to proceed with BAM15 despite the complete absence of human safety data, the harm-reduction version of "beginner" information is the following: start with the lowest reported research-vendor dose (typically 5-10 mg orally once daily, but these doses are not validated and vendor content is not verified); take it in the morning to avoid sleep disruption from thermogenesis and sympathetic activation; do not combine with any other metabolic compound, stimulant, thyroid agent, or GLP-1 agonist; maintain hydration aggressively because uncoupling increases fluid loss through sweating; monitor oral temperature daily before dosing and at 2-4 hours after dosing to detect excess thermogenesis; check resting heart rate and blood pressure at the same timepoints; stop immediately if oral temperature exceeds 99.5F at rest, if resting heart rate is more than 15 bpm above baseline, if you experience uncontrolled sweating or excessive thirst, or if exercise capacity is significantly impaired; have a complete metabolic panel, liver function tests, and thyroid panel before starting and at 4 weeks if continuing; do not escalate the dose regardless of weight loss results; and commit in advance to stop after 4-6 weeks rather than continuing indefinitely. This protocol is harm reduction, not a recommendation. Each of these monitoring steps is inadequate substitute for the clinical trial data that does not exist. The reason people without medical training should not use uncouplers is that the toxicity profile is hard to recognize early — the warning signs (feeling warm, slightly sweaty, slightly fatigued) overlap with exercise, caffeine, excitement, and normal metabolism, and the transition from "mild signal that your body is uncoupled" to "dangerous hyperthermia and cardiovascular decompensation" can happen quickly at higher doses without obvious intermediate warnings. Clinicians managing DNP overdose in emergency departments describe patients who seemed fine 30 minutes before acute decompensation. This is not a compound where personal vigilance fully substitutes for clinical oversight, and personal vigilance is all a self-experimenter has.
The concept of an "intermediate" protocol for BAM15 is a fiction, because there is no dose-response data in humans to define what intermediate means, no pharmacokinetic data to determine whether twice-daily dosing is appropriate, and no efficacy data to establish when escalation is justified. The honest presentation of what people are doing in practice is as follows, with the understanding that describing a practice is not endorsing it. Research-chemical vendor documentation and self-report communities suggest an "intermediate" BAM15 protocol ranges from 15-30 mg orally daily, either as a single morning dose or divided into two doses 8-12 hours apart. The rationale for divided dosing is that uncoupling intensity is proportional to circulating drug concentration, and spreading the dose produces a smoother metabolic effect without sharp peaks in thermogenesis. The counterargument is that divided dosing extends the thermogenic signal across more of the day, increasing cumulative heat load and making sleep harder if the second dose is in the afternoon. Neither position is supported by clinical data. Duration at this range in self-reports is typically 4-8 weeks before either cycling off or dose adjustment, and the practical reality is that most self-experimenters stop earlier because of tolerability issues (fatigue, reduced exercise tolerance, excessive sweating, insomnia) rather than because of a planned endpoint. For monitoring at the intermediate range, the same metrics as the beginner protocol become more important: daily oral temperature before and after dosing, resting heart rate trends, body weight and body composition tracking (ideally weekly DEXA or equivalent), comprehensive metabolic panel every 2-4 weeks to detect electrolyte disturbances and liver enzyme changes, thyroid function tests to distinguish uncoupler thermogenesis from thyroid dysfunction, and fasting glucose and insulin to track metabolic changes. Symptoms that should trigger dose reduction or cessation include persistent elevated body temperature, sustained tachycardia at rest, exercise intolerance disproportionate to the intended metabolic demand, unexplained muscle soreness or weakness (possible rhabdomyolysis signal), dark urine, jaundice, confusion, or any symptoms suggestive of cardiac arrhythmia. The combination patterns people use in practice at this stage often include creatine for muscle preservation during caloric deficit, whey protein for satiety and muscle retention, aggressive electrolyte replacement (sodium, potassium, magnesium) because uncoupler-induced sweating and increased renal perfusion accelerate electrolyte loss, and sometimes L-Carnitine for fatty acid substrate provision. These combinations do not have clinical evidence for safety with BAM15, but they address the physiological demands that uncoupling places on the body. Exercise during BAM15 use at this dose range becomes a judgment call. Light to moderate cardiovascular exercise (walking, easy cycling, swimming at conversational pace) is usually tolerated and may amplify the weight-loss effect through increased substrate oxidation. High-intensity intervals, heavy resistance training, and long-duration endurance work often become unsustainable because mitochondrial ATP synthesis is compromised relative to what these modalities demand. The practical implication is that weight loss on BAM15 tends to come from reduced fat mass AND reduced lean mass if training volume is cut in response to fatigue, which may be counterproductive for body composition goals. The contrast with GLP-1 agonists or bariatric surgery is instructive — those interventions produce weight loss primarily through reduced intake, which preserves the capacity to train hard on the reduced energy available, whereas uncouplers produce weight loss partly through reduced output capacity, which makes maintaining training volume harder. People who have used BAM15 and subsequently tried semaglutide or tirzepatide generally report that the GLP-1 agonists produced more sustainable body composition improvement with less subjective metabolic strain, although this is anecdotal. The intermediate protocol period is the stage where people who are going to have a bad outcome with BAM15 are most likely to have it — the honeymoon tolerability of the first week or two is gone, cumulative stress on mitochondria and thermoregulation has accumulated, and there is a temptation to push the dose higher in pursuit of continued weight loss. The clinical recommendation, such as it exists, is that if results at 15-30 mg daily are not sufficient, the appropriate response is to stop and reassess rather than escalate to an advanced protocol for which there is even less justification.
No advanced protocol for BAM15 is supported by any credible source, and this section is included exclusively to document what is being attempted in practice so that clinicians encountering patients who have used these doses can understand the exposure. The research-chemical and self-report community describes "advanced" BAM15 dosing at 40-60 mg daily, occasionally higher, typically in people who have been on lower doses for several weeks without sufficient weight loss and who are attempting to accelerate results. There is no basis for this escalation. The rodent efficacy data plateau at doses that, accounting for body surface area scaling, translate to roughly 20-30 mg daily in a 70 kg human — doses above that range in animals typically produce diminishing returns on weight loss with increasing toxicity signals. The concept that "more is better" in uncoupler dosing is directly contradicted by the DNP clinical literature, which found that fat loss saturates at doses well below the toxic range and that the dose-response curve for hyperthermia and mortality is steeper than the dose-response curve for weight loss, meaning higher doses push you further into the toxicity zone faster than they push you further into the efficacy zone. People who are dosing BAM15 at 40-60 mg daily report substantially worse tolerability than at lower doses: persistent warmth and sweating that interferes with daily activities, noticeable impairment of exercise tolerance, fatigue that is not relieved by rest, insomnia from sympathetic activation, and subjective "feeling wrong" that is hard to quantify but consistently described. These are the symptoms that would be expected if mitochondrial ATP synthesis is becoming rate-limiting and the body is mobilizing compensatory mechanisms that themselves have costs. The appropriate clinical response to these symptoms is immediate cessation, not persistence. The risks at this dose range, extrapolated from uncoupler toxicology, include: acute hepatotoxicity from high circulating drug concentrations undergoing hepatic metabolism; rhabdomyolysis from mitochondrial dysfunction in skeletal muscle combined with exercise or physical stress; cardiac arrhythmias from combined sympathetic activation and altered cellular energetics; thermoregulatory failure during exertion, hot environments, or febrile illness (a common cold becomes more dangerous when baseline thermogenesis is elevated); and long-term toxicities such as cataracts and peripheral neuropathy that may not manifest during the dosing period but accumulate with exposure. The duration of advanced-dose use is, in self-reports, usually limited by tolerability rather than by planned endpoint — most people cannot sustain 40-60 mg daily for more than 2-4 weeks before symptoms force cessation, which is probably a protective feature of the compound rather than a limitation. The scenarios where clinicians see patients who have used advanced BAM15 doses are typically in emergency departments with heat-related illness, in primary care with unexplained abnormal liver enzymes or electrolyte disturbances, and in specialty clinics where patients disclose research-chemical use after other diagnostic workup has been negative. If you are a patient reading this after using BAM15 at this dose range, the correct action is to stop immediately, seek evaluation from a physician you can trust with honest disclosure of what you have taken, and provide this context so your provider can order the appropriate labs (CMP, CK, LFTs, TSH, troponin if cardiac symptoms, urinalysis). Most acute toxicity reverses with cessation over days to weeks, but delayed effects on hepatic function, thyroid axis recovery, and mitochondrial biogenesis may persist longer. If you are considering escalating to this dose range, the information above is offered in the hope that you will reconsider. The clinical and metabolic ceiling on BAM15 at lower doses is not higher than what is achievable with fully optimized training, nutrition, sleep, and (where indicated) FDA-approved metabolic pharmacology. Pushing an unvalidated research chemical into toxicity to chase an additional pound of weight loss is a pattern that ends badly often enough that it should not be the strategy anyone pursues. The single most valuable piece of advice for the advanced-protocol question is to consider whether the underlying goal — faster fat loss, better body composition, improved metabolic markers — might be better served by stopping BAM15 entirely and moving to interventions with safety data, predictable dose-response, and supportive clinical infrastructure.
Commonly Stacked With
BAM15 is not a compound that should be stacked with anything, because BAM15 should not be used at all outside of a properly designed clinical trial, and adding other metabolic interventions to an unvalidated research chemical compounds the unknown risks. That said, the reality is that people who are using BAM15 often are already using other metabolic compounds, and harm-reduction information about likely interactions is more useful than pretending the question does not exist. With GLP-1 receptor agonists — Semaglutide, Tirzepatide, Retatrutide, Mazdutide, Orforglipron, Cagrilintide — the combination is theoretically problematic because both reduce caloric intake (GLP-1) and increase caloric expenditure (BAM15), producing additive weight loss that may exceed what is physiologically sustainable, along with potential for severe hypoglycemia if insulin secretion is altered. GLP-1 agonists also reduce appetite to a degree that may mask early signs of over-uncoupling such as fatigue and reduced food intake, making it harder to detect dose escalation problems. If you are on a GLP-1 agonist, the rational position is that the GLP-1 is already producing the metabolic benefit BAM15 is supposed to produce, with enormously better safety data and with FDA approval, and layering BAM15 on top is pure risk without additional benefit. With Tesofensine, a triple monoamine reuptake inhibitor, the combination adds sympathomimetic burden (tachycardia, hypertension, insomnia) to uncoupler-induced thermogenesis and sympathetic activation, which is a particularly bad combination for cardiovascular safety. With thyroid hormone replacement (T4, T3), the combination is redundant at the mechanism level (both increase metabolic rate) and dangerous in terms of hyperthyroid symptoms, palpitations, and cardiovascular strain. With AOD-9604, a lipolytic fragment of growth hormone, the combination is theoretically synergistic for fat loss but has no clinical basis and compounds the unknown safety profile. With mitochondrial support supplements — L-Carnitine, Coenzyme Q10, NAD+, Creatine — the rationale is that uncoupling places high demand on mitochondrial substrate shuttling and NAD+/NADH cycling, and supporting those pathways may reduce fatigue and exercise intolerance from BAM15 dosing. There is no clinical evidence this combination improves outcomes or safety with BAM15, but the components are individually well-tolerated and the mechanistic logic is coherent if someone is determined to proceed with uncoupler dosing. With antioxidants — Glutathione, N-acetylcysteine, alpha-lipoic acid, vitamin C, vitamin E — the situation is more nuanced. BAM15 itself reduces mitochondrial ROS generation by accelerating electron transport, so the intuition that antioxidants are needed to counter oxidative stress is probably incorrect with mild uncoupling. At higher doses where uncoupling is severe enough to cause cellular stress, antioxidants may not be able to rescue mitochondrial function. With Humanin and other mitochondrial-derived peptides, the theoretical overlap is attractive — both affect mitochondrial function — but there is no evidence for or against the combination. With Methylene Blue, which donates electrons to Complex IV and can act as an alternative electron carrier, the combination is mechanistically interesting but completely unstudied. With resistance training and cardiovascular exercise, BAM15 theoretically reduces exercise capacity because ATP synthesis is partially short-circuited, which means workouts feel harder at the same absolute intensity and recovery may be delayed. With cold exposure (ice baths, cold plunges, cold air), the combination stacks thermogenic stimuli in a way that could produce either exaggerated metabolic effect or cardiovascular stress, and the balance is not predictable. With fasting and caloric restriction, uncouplers and negative energy balance are mechanistically related (both force the body to burn stored substrate), and the combination may amplify weight loss at the cost of increased fatigue, worsened thyroid suppression, and greater risk of muscle loss. With alcohol, the combination is clearly dangerous because alcohol impairs mitochondrial function independently and amplifies uncoupler-induced hepatic stress. With stimulants (caffeine, yohimbine, amphetamines, ADHD medications), the combination compounds sympathetic activation, cardiovascular load, and thermogenic stimulus — this is the stacking pattern most associated with DNP deaths in the case report literature and should be avoided entirely with any uncoupler.
Side Effects & Safety
Contraindications
The list of absolute contraindications to BAM15 is long precisely because the compound is uncharacterized in humans, and in the absence of data most physiologic conditions that could plausibly interact badly with mitochondrial uncoupling are presumed contraindications. Anyone with known or suspected heart disease should not use BAM15 — protonophore-induced increases in heart rate and cardiac metabolic demand are theoretically dangerous in the setting of coronary artery disease, heart failure, arrhythmias, cardiomyopathy, or structural heart disease. This includes patients with a history of myocardial infarction, stent placement, coronary artery bypass grafting, congenital heart disease, or implanted cardiac devices (pacemaker, ICD). Anyone with hyperthyroidism or untreated thyroid nodules should not use BAM15 because the metabolic profile overlaps with thyroid excess and the combination amplifies cardiovascular and thermoregulatory risk. Patients on thyroid hormone replacement (levothyroxine, liothyronine) are a related contraindication because the dose of thyroid hormone is titrated to a specific metabolic setpoint and adding an uncoupler disturbs that setpoint in ways that are hard to anticipate. Anyone with hepatic impairment — active hepatitis, cirrhosis, significant fatty liver with elevated enzymes, or prior drug-induced liver injury — should avoid BAM15 because hepatic metabolism of the compound is uncharacterized and liver stress from mitochondrial dysfunction is theoretically additive to pre-existing liver pathology. Anyone with renal impairment should avoid BAM15 because uncoupler-induced increases in metabolic rate and fluid losses can precipitate renal dysfunction, and drug elimination pathways are not characterized. Pregnancy and breastfeeding are absolute contraindications — no reproductive toxicology data exist in humans, and the rodent data for DNP suggest uncouplers in general are teratogenic and should not be used during gestation. Anyone trying to conceive, male or female, should avoid BAM15 because reproductive effects are unknown and the cost of caution is low. Children and adolescents should not use BAM15 under any circumstances; the compound has not been studied in developmental age groups and the metabolic effects are not appropriate for anyone whose growth and maturation is ongoing. Anyone with a history of heat-related illness — heat stroke, heat exhaustion, malignant hyperthermia, neuroleptic malignant syndrome, serotonin syndrome — should absolutely avoid uncouplers because baseline thermoregulatory vulnerability is amplified by the mechanism. Anyone with seizure disorders should avoid BAM15 because thermogenesis, electrolyte shifts, and cellular energy stress are seizure triggers in susceptible individuals. Anyone with a history of rhabdomyolysis, statin-induced myopathy, or mitochondrial myopathy should avoid BAM15 because muscle tissue is particularly vulnerable to uncoupler-induced ATP stress. Anyone with eating disorders — anorexia nervosa, bulimia nervosa, binge eating disorder, body dysmorphia — should not use any compound that increases metabolic rate, because the underlying disorder is likely to drive inappropriate use and the compound will compound medical complications. Relative contraindications that warrant physician involvement if dosing is being considered at all include: type 1 diabetes (glucose management becomes more difficult with altered substrate utilization); type 2 diabetes on insulin (hypoglycemia risk); adrenal insufficiency; inflammatory bowel disease; autoimmune disease requiring immunomodulatory therapy; significant mental health conditions where medications might interact; and concurrent use of any metabolic pharmacology including GLP-1 agonists, SGLT2 inhibitors, metformin at doses above 1500 mg/day, bupropion, phentermine, topiramate, or naltrexone. Medications that interact pharmacokinetically with BAM15 are largely uncharacterized because no drug-drug interaction studies exist. Theoretical interactions include: anything that shares hepatic metabolism pathways (CYP3A4 substrates most likely); anything that increases sympathetic tone (amphetamines, caffeine at high intake, nicotine, decongestants); anything that increases core temperature (MAO inhibitors, SSRIs with serotonin syndrome potential, anticholinergics that impair sweating, antipsychotics); and anything that impairs renal or hepatic clearance. The correct framing is that BAM15 has been studied in rodents and not in humans, and any patient on any prescription medication should assume interactions are possible and discuss the situation with a physician — preferably one with expertise in clinical pharmacology rather than one being asked to rubber-stamp a decision already made. The final contraindication, which is the most important one, is the lack of a clinically overseen dosing and monitoring environment. If you do not have a physician who knows you are taking BAM15, who has access to your complete medical history, who can order appropriate labs and adjust or stop dosing based on findings, and who can evaluate you urgently if adverse effects develop, then you do not have the minimum supportive infrastructure for safe self-experimentation with this compound. That is not a contraindication because of any specific medical condition; it is a contraindication because uncoupler toxicity is not safely managed by an untrained person working alone, and the first adverse event is a worse time to build clinical infrastructure than the day before dosing began.
Additional Notes
There is no validated dosing regimen for BAM15 because no Phase 1 trial has established a human dose-response curve, and anyone quoting a specific recommended dose is extrapolating from rodent studies or research-chemical vendor marketing without clinical validation. The dose ranges described in the protocol sections above — 5-10 mg daily as a starting range, 15-30 mg daily in a self-experimenter "intermediate" range, 40-60 mg daily in a higher-risk "advanced" range — are drawn from self-report forums and research-chemical vendor guidance, not from controlled studies. Vendor documentation is not reliable because the compounds sold as BAM15 from research-chemical suppliers are not subject to pharmaceutical-grade quality control, and independent analytical testing of various vendor products has shown variable content, variable purity, and occasional misidentification of the active pharmaceutical ingredient. A "10 mg dose" from one vendor is not necessarily equivalent to a "10 mg dose" from another vendor, which makes any dose recommendation effectively meaningless without reference to a specific verified supply. If BAM15 were to enter clinical development and emerge as an approved drug, the likely dose range based on rodent efficacy studies and allometric scaling would be in the 10-40 mg daily range for metabolic indications, with dose titration over several weeks to identify the minimum effective dose for each patient. This is the same pattern followed with other metabolic drugs — start low, titrate up based on tolerability and response, settle at the dose that produces the desired effect with acceptable side effects. In practice for self-experimenters, the intuition of "start low, go slow" applies but cannot be executed with confidence because the research-chemical supply does not provide dose consistency. Administration is typically oral, with BAM15 taken as a powder suspended in a lipid-containing vehicle (MCT oil, coconut oil) or as a dissolved solution. Oral bioavailability in humans is unknown. In rodent studies, BAM15 is typically given in DMSO-based vehicles or mixed into food, and the pharmacokinetics have not been fully characterized. Timing recommendations from self-reports generally favor morning dosing to avoid thermogenesis-related sleep disruption, with food to reduce gastrointestinal tolerability issues. Half-life in humans is unknown. The plasma half-life of BAM15 in mice has been reported in the 4-8 hour range in some studies, which if roughly conserved in humans would support once-daily dosing for steady-state effect, but human pharmacokinetics cannot be assumed from rodent data. Accumulation with repeated dosing is possible if elimination is slow relative to the dosing interval, which is an additional concern because the dose quoted on a vendor label may produce cumulative effects over weeks that are not apparent in acute tolerability. Duration of use in self-reports is typically 4-8 weeks, with cycles separated by equal or longer washout periods. There is no rationale for indefinite continuous dosing of an unvalidated uncoupler, and the burden of cumulative mitochondrial and thermoregulatory stress is likely to outweigh any incremental metabolic benefit past a limited window. Missed doses should not be made up because the intent is to avoid peak exposures, not to maintain steady-state concentrations of a compound whose target concentration is unknown. Overdose, even by a factor of 2-3x, is dangerous and should be treated as a medical emergency with aggressive cooling, fluid support, and emergency department evaluation — protonophore toxicity does not respond to typical antipyretic measures because the heat is not prostaglandin-mediated. The only clinically defensible position on BAM15 dosing is that the validated dose is zero until a legitimate trial provides different information. Every other number is a guess with a patina of precision that belies the underlying uncertainty.
Frequently Asked Questions
What is the recommended BAM15 dosage?
The typical dose range for BAM15 is Research compound — no established human doses. Animal studies use 10-100 mg/kg. Always start with the lowest effective dose.
How often should I take BAM15?
Administration frequency depends on the specific protocol. Consult current research literature.
Does BAM15 need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are BAM15 side effects?
Because no human trials of BAM15 have been conducted, the side effect profile is reconstructed from rodent toxicology, in vitro cellular data, and a small number of self-reports from people who have obtained the compound from research-chemical vendors. The rodent data are reassuring compared to DNP: Alexopoulos et al. 2020 reported no significant hyperthermia, no tachycardia, no liver enzyme elevation, and no mortality at doses that produced clear weight loss and metabolic benefit in diet-induced obese mice ([Alexopoulos et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32913312/)). In direct comparisons, doses of DNP that produced equivalent weight loss caused marked hyperthermia and fatal outcomes in a subset of animals, whereas BAM15 did not. Axelrod et al. 2022 reported similar tolerability in rats on 8-week dosing ([Axelrod et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35046610/)). However, these studies used specific dose ranges, specific vehicle formulations, and specific rodent strains under controlled lab conditions, and extrapolating from these data to human safety at arbitrary doses obtained from research-chemical vendors is not valid. The theoretical side effect profile of mitochondrial uncouplers includes: hyperthermia from excess heat production, which at extreme levels can cause multi-organ failure and death; sweating, thirst, and fluid shifts from increased metabolic rate; fatigue and exercise intolerance at higher doses because mitochondrial ATP synthesis becomes rate-limiting; tachycardia and palpitations from sympathetic activation; cataracts — DNP causes cataracts in animals and humans, possibly through effects on lens metabolism, and whether BAM15 shares this toxicity is unknown; peripheral neuropathy, which is documented with prolonged DNP use and again has unknown applicability to BAM15; hepatotoxicity, which is not reported in rodent studies but remains a concern for any compound undergoing hepatic metabolism at meaningful doses; and rhabdomyolysis, which has been reported in humans using DNP and which could theoretically occur with any uncoupler that pushes mitochondrial function beyond the capacity of muscle tissue. Self-reports from people using BAM15 sourced from research-chemical vendors describe a profile that includes noticeable warming and increased perspiration at higher doses, increased thirst, mild fatigue and reduced exercise tolerance, occasional nausea, and subjective appetite reduction — but these reports are unverified, uncontrolled for placebo, unquantified in terms of actual dose delivered (because vendor purity and content are unverified), and occur in a population that has almost certainly used other compounds concurrently. They are not a substitute for clinical data. The acute overdose signature of uncoupler toxicity, which is well documented with DNP and theoretically applies to any protonophore, is progressive hyperthermia that does not respond to antipyretics (because the heat is generated at the mitochondrial level, not through prostaglandin pathways), tachycardia, agitation, sweating, and eventually seizures, rhabdomyolysis, renal failure, and cardiovascular collapse. There is no antidote. Treatment is aggressive cooling, fluid resuscitation, and supportive care in an ICU. Mortality from DNP overdose is high even with optimal medical management because the uncoupling does not reverse quickly. Anyone using BAM15 needs to understand this toxicity pattern exists as a theoretical possibility even if rodent data suggest BAM15 is safer than DNP at therapeutic doses — because the research-chemical supply chain does not guarantee dose accuracy, and a small overdose of a dangerous compound produces disproportionately dangerous consequences. The appropriate response to the first signs of excess thermogenesis (persistent elevated body temperature, uncontrolled sweating, racing heart at rest) is to stop dosing immediately and seek medical evaluation. The appropriate response to suspected severe toxicity is emergency department evaluation with honest disclosure of what was taken — protonophore toxicity is managed differently from sepsis, thyroid storm, or sympathomimetic overdose, and physicians need to know what they are treating.
Where can I buy BAM15?
Visit our vendor directory to find trusted sources for BAM15.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.